{"id":{"repo_id":"tuebingen","oai_identifier":"oai:publikationen.uni-tuebingen.de:10900/173305"},"canonical_url":"https://search.dev.ndltd.org/etd/tuebingen/oai:publikationen.uni-tuebingen.de:10900/173305","repository":{"repo_id":"tuebingen","name":"Universität Tübingen","base_url":"https://publikationen.uni-tuebingen.de/oai/request"},"display":{"title":"Post-Pandemic Serosurveillance of RSV and Influenza: Development and Application of Multiplex Immunoassays","abstract":"With seasonal epidemics each year and several global pandemics, respiratory viruses represent a significant global health burden. Respiratory syncytial virus (RSV) and Influ- enza viruses are of particular concern as they have a severe impact on vulnerable popu- lations such as infants and the elderly and can trigger global pandemics through antigenic drift or zoonotic transmission. The disruption of viral seasonality caused by the SARS- CoV-2 pandemic has hampered continuous epidemiologic surveillance and highlighted the need for reliable serologic tools to assess immunity and infection status at the popu- lation level in times of limited clinical surveillance. The aim of this thesis was to develop and validate two antibody binding multiplex immu- noassays, RSV MIA and FLU MIA, that enable sensitive and subtype-resolved detection of virus-specific antibody responses in both serum and other sample matrixes. These as- says were then used to generate population-level serological data on RSV and Influenza immunity and infections within a longitudinal retrospective cohort study. The assays were then also used to investigate vaccine-induced immune responses, such as Influenza an- tibodies produced in an organ-on-chip model system. To achieve this, I developed and validated the RSV MIA and the FLU MIA according to EMA and FDA guidelines, enabling robust high-throughput quantification of antigen-specific antibody titers. To determine assay performance and to understand the immune response to an RSV/Influenza infec- tion, both assays were clinically validated using samples from human challenge studies. When used in a longitudinal population cohort study, RSV MIA could be used to identify seasonal RSV infections, often including the viral subtype. FLU MIA showed high sensitiv- ity in detecting broad and strain-specific humoral responses after both influenza vaccina- tion and seasonal infection, including seasonal patterns induced by circulating influenza strains between years. In the organ-on-chip system, FLU MIA successfully quantified an- tigen-specific antibodies in response to vaccine administration, confirming the ability of lymphoid tissue to elicit measurable immune responses ex vivo. Taken together, these re- sults underscore the versatility of both assays for seroepidemiologic studies and vaccine testing platforms. By enabling detailed analyses of infection- and vaccine-induced hu- moral immunity, these assays provide a valuable foundation for future epidemiologic sur- veillance and next-generation vaccine evaluation.","abstract_html":"With seasonal epidemics each year and several global pandemics, respiratory viruses represent a significant global health burden. Respiratory syncytial virus (RSV) and Influ- enza viruses are of particular concern as they have a severe impact on vulnerable popu- lations such as infants and the elderly and can trigger global pandemics through antigenic drift or zoonotic transmission. The disruption of viral seasonality caused by the SARS- CoV-2 pandemic has hampered continuous epidemiologic surveillance and highlighted the need for reliable serologic tools to assess immunity and infection status at the popu- lation level in times of limited clinical surveillance. The aim of this thesis was to develop and validate two antibody binding multiplex immu- noassays, RSV MIA and FLU MIA, that enable sensitive and subtype-resolved detection of virus-specific antibody responses in both serum and other sample matrixes. These as- says were then used to generate population-level serological data on RSV and Influenza immunity and infections within a longitudinal retrospective cohort study. The assays were then also used to investigate vaccine-induced immune responses, such as Influenza an- tibodies produced in an organ-on-chip model system. To achieve this, I developed and validated the RSV MIA and the FLU MIA according to EMA and FDA guidelines, enabling robust high-throughput quantification of antigen-specific antibody titers. To determine assay performance and to understand the immune response to an RSV/Influenza infec- tion, both assays were clinically validated using samples from human challenge studies. When used in a longitudinal population cohort study, RSV MIA could be used to identify seasonal RSV infections, often including the viral subtype. FLU MIA showed high sensitiv- ity in detecting broad and strain-specific humoral responses after both influenza vaccina- tion and seasonal infection, including seasonal patterns induced by circulating influenza strains between years. In the organ-on-chip system, FLU MIA successfully quantified an- tigen-specific antibodies in response to vaccine administration, confirming the ability of lymphoid tissue to elicit measurable immune responses ex vivo. Taken together, these re- sults underscore the versatility of both assays for seroepidemiologic studies and vaccine testing platforms. By enabling detailed analyses of infection- and vaccine-induced hu- moral immunity, these assays provide a valuable foundation for future epidemiologic sur- veillance and next-generation vaccine evaluation.","abstract_has_math":false,"creators":["Marsall, Patrick"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026-11-30","date_published":"2026-11-30","updated_at":"2026-08-21T22:21:56Z","subjects":[],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["hdl:10900/173305"],"render_values":[{"text":"hdl:10900/173305","href":null,"code":true}]}]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null},"source_record":{"url":"https://publikationen.uni-tuebingen.de/oai/request?verb=GetRecord&metadataPrefix=mets&identifier=oai%3Apublikationen.uni-tuebingen.de%3A10900%2F173305","prefix":"mets"},"metadata_groups":[{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.issued","label":"Date","values":["2026-11-30"]},{"key":"dc:type","label":"Dc Type","values":["PhDThesis"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["hdl:10900/173305"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.other","label":"Dc Description Other","values":["With seasonal epidemics each year and several global pandemics, respiratory viruses represent a significant global health burden. Respiratory syncytial virus (RSV) and Influ- enza viruses are of particular concern as they have a severe impact on vulnerable popu- lations such as infants and the elderly and can trigger global pandemics through antigenic drift or zoonotic transmission. The disruption of viral seasonality caused by the SARS- CoV-2 pandemic has hampered continuous epidemiologic surveillance and highlighted the need for reliable serologic tools to assess immunity and infection status at the popu- lation level in times of limited clinical surveillance. The aim of this thesis was to develop and validate two antibody binding multiplex immu- noassays, RSV MIA and FLU MIA, that enable sensitive and subtype-resolved detection of virus-specific antibody responses in both serum and other sample matrixes. These as- says were then used to generate population-level serological data on RSV and Influenza immunity and infections within a longitudinal retrospective cohort study. The assays were then also used to investigate vaccine-induced immune responses, such as Influenza an- tibodies produced in an organ-on-chip model system. To achieve this, I developed and validated the RSV MIA and the FLU MIA according to EMA and FDA guidelines, enabling robust high-throughput quantification of antigen-specific antibody titers. To determine assay performance and to understand the immune response to an RSV/Influenza infec- tion, both assays were clinically validated using samples from human challenge studies. When used in a longitudinal population cohort study, RSV MIA could be used to identify seasonal RSV infections, often including the viral subtype. FLU MIA showed high sensitiv- ity in detecting broad and strain-specific humoral responses after both influenza vaccina- tion and seasonal infection, including seasonal patterns induced by circulating influenza strains between years. In the organ-on-chip system, FLU MIA successfully quantified an- tigen-specific antibodies in response to vaccine administration, confirming the ability of lymphoid tissue to elicit measurable immune responses ex vivo. Taken together, these re- sults underscore the versatility of both assays for seroepidemiologic studies and vaccine testing platforms. By enabling detailed analyses of infection- and vaccine-induced hu- moral immunity, these assays provide a valuable foundation for future epidemiologic sur- veillance and next-generation vaccine evaluation.","Dissertation ist gesperrt bis 30. November 2026 !"]},{"key":"dc:title","label":"Title","values":["Post-Pandemic Serosurveillance of RSV and Influenza: Development and Application of Multiplex Immunoassays"]}]}],"canonical_facts":{"dc:date.issued":["2026-11-30"],"dc:description.other":["With seasonal epidemics each year and several global pandemics, respiratory viruses represent a significant global health burden. Respiratory syncytial virus (RSV) and Influ- enza viruses are of particular concern as they have a severe impact on vulnerable popu- lations such as infants and the elderly and can trigger global pandemics through antigenic drift or zoonotic transmission. The disruption of viral seasonality caused by the SARS- CoV-2 pandemic has hampered continuous epidemiologic surveillance and highlighted the need for reliable serologic tools to assess immunity and infection status at the popu- lation level in times of limited clinical surveillance. The aim of this thesis was to develop and validate two antibody binding multiplex immu- noassays, RSV MIA and FLU MIA, that enable sensitive and subtype-resolved detection of virus-specific antibody responses in both serum and other sample matrixes. These as- says were then used to generate population-level serological data on RSV and Influenza immunity and infections within a longitudinal retrospective cohort study. The assays were then also used to investigate vaccine-induced immune responses, such as Influenza an- tibodies produced in an organ-on-chip model system. To achieve this, I developed and validated the RSV MIA and the FLU MIA according to EMA and FDA guidelines, enabling robust high-throughput quantification of antigen-specific antibody titers. To determine assay performance and to understand the immune response to an RSV/Influenza infec- tion, both assays were clinically validated using samples from human challenge studies. When used in a longitudinal population cohort study, RSV MIA could be used to identify seasonal RSV infections, often including the viral subtype. FLU MIA showed high sensitiv- ity in detecting broad and strain-specific humoral responses after both influenza vaccina- tion and seasonal infection, including seasonal patterns induced by circulating influenza strains between years. In the organ-on-chip system, FLU MIA successfully quantified an- tigen-specific antibodies in response to vaccine administration, confirming the ability of lymphoid tissue to elicit measurable immune responses ex vivo. Taken together, these re- sults underscore the versatility of both assays for seroepidemiologic studies and vaccine testing platforms. By enabling detailed analyses of infection- and vaccine-induced hu- moral immunity, these assays provide a valuable foundation for future epidemiologic sur- veillance and next-generation vaccine evaluation.","Dissertation ist gesperrt bis 30. November 2026 !"],"dc:identifier":["hdl:10900/173305"],"dc:title":["Post-Pandemic Serosurveillance of RSV and Influenza: Development and Application of Multiplex Immunoassays"],"dc:type":["PhDThesis"]},"updated_at":"2026-08-21T22:21:56Z"}